Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Real-time Estimate Cboe Europe  -  07:36:28 2023-01-31 am EST
82.73 CHF   -0.54%
01/30Novartis' Sandoz Unit Wins EU Health Agency Panel's Backing for Humira Biosimilar
MT
01/30Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
GL
01/30Novartis : Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Intron Health Lifts Price Target on Novartis, Maintains Buy Recommendation

11/30/2022 | 05:00am EST


ę MT Newswires 2022
All news about NOVARTIS AG
01/30Novartis' Sandoz Unit Wins EU Health Agency Panel's Backing for Humira Biosimilar
MT
01/30Sandoz receives positive CHMP opinion for citrate-free high concentration formulation o..
GL
01/30Novartis : Sandoz receives positive CHMP opinion for citrate-free high concentr..
DJ
01/27Novartis Says Initial Data from Phase 3 Trial Show No Difference Between Crizanlizumab,..
MT
01/27Novartis : provides update on Phase III STAND trial assessing crizanlizumab
PU
01/25Novartis Files Petition With Supreme Court to Protect Gilenya Patent
MT
01/25NOVARTIS AG : Sell rating from Barclays
MD
01/25Deciphex Limited announced that it has received €14.8 million in funding from a gr..
CI
01/24Global markets live: GE, J&J, Verizon, Lockheed Martin, Halliburton...
MS
01/24Europe's revenue growth expected to slow to a crawl in Q4
RE
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2022 51 352 M - -
Net income 2022 8 563 M - -
Net Debt 2022 7 321 M - -
P/E ratio 2022 22,1x
Yield 2022 3,69%
Capitalization 194 B 194 B -
EV / Sales 2022 3,91x
EV / Sales 2023 3,86x
Nbr of Employees 108 000
Free-Float 87,1%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Last Close Price 90,05 $
Average target price 96,60 $
Spread / Average Target 7,27%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-0.50%193 693
JOHNSON & JOHNSON-8.29%423 546
ELI LILLY AND COMPANY-6.49%323 536
NOVO NORDISK A/S2.51%317 108
ROCHE HOLDING AG-0.79%275 846
MERCK & CO., INC.-4.38%268 980